Recruiting × Immunoglobulin Light-chain Amyloidosis × Clear all Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
Phase 1 Recruiting
24 enrolled
ALACRITY
Phase 1/2 Recruiting
91 enrolled
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Phase NA Recruiting
41 enrolled
Rapid dFLC Response Predict CHR in AL Amyloidosis
Recruiting
50 enrolled
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Phase 1/2 Recruiting
49 enrolled
GlycAL
Recruiting
100 enrolled
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Phase 3 Recruiting
15 enrolled
BE.Amycon Biobank & Data Registry UZ Leuven
Recruiting
505 enrolled
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Phase 1/2 Recruiting
37 enrolled
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Phase 2 Recruiting
96 enrolled
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Recruiting
10,000 enrolled
CArdiag
Phase 3 Recruiting
200 enrolled
Teclistamab-Daratumumab in AL Amyloidosis
Phase 2 Recruiting
25 enrolled
MICA
Phase NA Recruiting
171 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
Phase 2 Recruiting
30 enrolled
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Phase 2 Recruiting
120 enrolled
EAR
Recruiting
400 enrolled
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Recruiting
400 enrolled
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Phase 2 Recruiting
35 enrolled
NEXICART-2
Phase 1/2 Recruiting
40 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Phase 1/2 Recruiting
53 enrolled
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled
Teclistamab in Previously Treated AL Amyloidosis
Phase 2 Recruiting
30 enrolled
Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis
Phase NA Recruiting
30 enrolled
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Phase 2 Recruiting
180 enrolled
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Phase NA Recruiting
69 enrolled
Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
Phase NA Recruiting
20 enrolled
ICAR
Recruiting
300 enrolled
NIMMS
Recruiting
400 enrolled
ITA-WebNet
Recruiting
1,000 enrolled
B-SCR-MM
Recruiting
5,000 enrolled
ReAL
Recruiting
5,000 enrolled
EUREKA
Recruiting
400 enrolled
ProDigALIty
Recruiting
760 enrolled
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
Phase 2 Recruiting
20 enrolled
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study
Phase NA Recruiting
20 enrolled
Daratumumab for Patients With Light Chain Amyloidosis
Phase NA Recruiting
100 enrolled
AT02-001
Phase 1 Recruiting
100 enrolled
FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Phase 1 Recruiting
12 enrolled
RaDaR
Recruiting
35,000 enrolled